FY2026 EPS Estimates for Nuvalent Lowered by Leerink Partnrs

Nuvalent, Inc. (NASDAQ:NUVL) – Equities researchers at Leerink Partnrs reduced their FY2026 earnings per share (EPS) estimates for shares of Nuvalent in a research note issued on Monday, November 17th. Leerink Partnrs analyst A. Berens now forecasts that the company will post earnings per share of ($6.33) for the year, down from their previous estimate of ($6.26). The consensus estimate for Nuvalent’s current full-year earnings is ($3.86) per share. Leerink Partnrs also issued estimates for Nuvalent’s FY2027 earnings at ($5.29) EPS.

Nuvalent (NASDAQ:NUVL) last announced its quarterly earnings data on Thursday, October 30th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.39) by ($0.31). During the same quarter last year, the firm earned ($1.28) EPS.

A number of other analysts also recently issued reports on the company. Wedbush reaffirmed an “outperform” rating and issued a $125.00 price objective (up previously from $120.00) on shares of Nuvalent in a research note on Monday. The Goldman Sachs Group upped their price objective on Nuvalent from $120.00 to $135.00 and gave the company a “buy” rating in a research report on Tuesday. HC Wainwright increased their target price on shares of Nuvalent from $130.00 to $155.00 and gave the company a “buy” rating in a research note on Monday. UBS Group lifted their price target on shares of Nuvalent from $114.00 to $132.00 and gave the stock a “buy” rating in a research note on Friday, October 31st. Finally, Stifel Nicolaus upped their price target on shares of Nuvalent from $115.00 to $135.00 and gave the company a “buy” rating in a report on Monday. Thirteen research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $137.69.

Nuvalent Stock Up 1.8%

NASDAQ NUVL traded up $1.91 on Thursday, reaching $109.04. The company had a trading volume of 118,905 shares, compared to its average volume of 534,640. The firm’s 50 day moving average price is $89.68 and its 200 day moving average price is $81.43. Nuvalent has a 12 month low of $55.53 and a 12 month high of $112.53. The stock has a market capitalization of $7.93 billion, a PE ratio of -20.48 and a beta of 1.31.

Institutional Trading of Nuvalent

A number of hedge funds have recently added to or reduced their stakes in NUVL. Vanguard Group Inc. increased its position in Nuvalent by 1.8% during the 3rd quarter. Vanguard Group Inc. now owns 4,605,007 shares of the company’s stock valued at $398,241,000 after purchasing an additional 80,883 shares during the period. Wellington Management Group LLP boosted its stake in shares of Nuvalent by 46.0% during the third quarter. Wellington Management Group LLP now owns 2,300,865 shares of the company’s stock valued at $198,979,000 after purchasing an additional 724,491 shares in the last quarter. State Street Corp boosted its stake in shares of Nuvalent by 4.2% during the second quarter. State Street Corp now owns 1,490,279 shares of the company’s stock valued at $113,708,000 after purchasing an additional 59,620 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Nuvalent by 11.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,450,602 shares of the company’s stock valued at $102,878,000 after buying an additional 152,692 shares during the period. Finally, Commodore Capital LP raised its stake in Nuvalent by 1.8% in the third quarter. Commodore Capital LP now owns 1,400,000 shares of the company’s stock worth $121,072,000 after buying an additional 25,000 shares in the last quarter. 97.26% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Nuvalent

In other Nuvalent news, insider Deborah Ann Miller sold 24,200 shares of the company’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $105.50, for a total value of $2,553,100.00. Following the completion of the sale, the insider directly owned 49,086 shares in the company, valued at approximately $5,178,573. This represents a 33.02% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO James Richard Porter sold 27,000 shares of the firm’s stock in a transaction on Thursday, October 16th. The shares were sold at an average price of $90.63, for a total value of $2,447,010.00. Following the transaction, the chief executive officer owned 249,062 shares in the company, valued at approximately $22,572,489.06. This represents a 9.78% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 291,000 shares of company stock worth $27,207,121 over the last three months. Company insiders own 10.20% of the company’s stock.

Nuvalent Company Profile

Nuvalent, Inc, a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.